The net profit for the corresponding quarter of the previous financial year stood at Rs 96 crore.
Further, the company’s board has recommended a dividend of Rs 35 per share for eligible shareholders. The details regarding the record and payout date for the same have not yet been provided by the company.
The company registered its revenue from operations for the quarter under review at Rs 1,046.4 crore, up from Rs 792.3 crore in the year-ago period.
For FY 2024-25, Bayer CropScience’s revenue from operations increased to Rs 5473.4 crore, compared to Rs 5106.2 crore in the previous year.
“Our Revenue from Operations grew by 7% for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayer’s reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs,” said Vinit Jindal, Executive Director and Chief Financial Officer of Bayer CropScience, while commenting on the Q4 results.
Also read: Olectra Greentech shares tank 13% as Maha gov reportedly cancels big e-bus order
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. It is engaged in the Agri Care business, which primarily includes the manufacture, sale and distribution of insecticides, fungicides, herbicides and various other agrochemical products and corn seeds.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)